Oppenheimer Upgrades Inspire Medical to Outperform with $85 Target After Q2 Beat
Company raises 2026 guidance and launches cost-cutting plan.
Already have an account? Sign in.
Company raises 2026 guidance and launches cost-cutting plan.
Skye Bioscience acquires Redx Pharma via UK scheme of arrangement. Combined company Fibrx focuses on RXC008 for Crohn’s fibrosis. Skye holders get only 5.38%.
FDA review papers reveal encouraging Week 52 eGFR findings (+5.2 placebo-adjusted) for TRUTAKNA in primary IgA nephropathy patients.
Key reason: rapid shift to >90% AI revenue and exclusive position in high-power reliability testing for advanced chips.